Literature DB >> 12631576

Disordered osteoclast formation and function in a CD38 (ADP-ribosyl cyclase)-deficient mouse establishes an essential role for CD38 in bone resorption.

Li Sun1, Jameel Iqbal, Svetlana Dolgilevich, Tony Yuen, Xue-Bin Wu, Baljit S Moonga, Olugbenga A Adebanjo, Peter J R Bevis, Frances Lund, Christopher L-H Huang, Harry C Blair, Etsuko Abe, Mone Zaidi.   

Abstract

We have evaluated the role of the ADP-ribosyl cyclase, CD38, in bone remodeling, a process by which the skeleton is being renewed constantly through the coordinated activity of osteoclasts and osteoblasts. CD38 catalyzes the cyclization of its substrate, NAD+, to the Ca2+-releasing second messenger, cyclic ADP-ribose (cADPr). We have shown previously that CD38 is expressed both in osteoblasts and osteoclasts. Its activation in the osteoclast triggers Ca2+ release through ryanodine receptors (RyRs), stimulation of interleukin-6 (IL-6), and an inhibition of bone resorption. Here, we have examined the consequences of deleting the CD38 gene in mice on skeletal remodeling. We report that CD38-/- mice displayed a markedly reduced bone mineral density (BMD) at the femur, tibia, and lumbar spine at 3 months and at the lumbar spine at 4 months, with full normalization of the BMD at all sites at 5 months. The osteoporosis at 3 months was accompanied by a reduction in primary spongiosa and increased osteoclast surfaces on histomorphometric analysis. Hematopoetic stem cells isolated ex vivo from CD38-/- mice showed a dramatic approximately fourfold increase in osteoclast formation in response to incubation for 6 days with RANK-L and M-CSF. The osteoclasts so formed in these cultures showed a approximately 2.5-fold increase in resorptive activity compared with wild-type cells. However, when adherent bone marrow stromal cells were allowed to mature into alkaline phosphatase-positive colony-forming units (CFU-Fs), those derived from CD38-/- mice showed a significant reduction in differentiation compared with wild-type cells. Real-time RT-PCR on mRNA isolated from osteoclasts at day 6 showed a significant reduction in IL-6 and IL-6 receptor mRNA, together with significant decreases in the expression of all calcineurin A isoforms, alpha, beta, and gamma. These findings establish a critical role for CD38 in osteoclast formation and bone resorption. We speculate that CD38 functions as a cellular NAD+ "sensor," particularly during periods of active motility and secretion.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12631576     DOI: 10.1096/fj.02-0205com

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  25 in total

1.  Extracellular NAD+ metabolism modulates osteoclastogenesis.

Authors:  Jameel Iqbal; Mone Zaidi
Journal:  Biochem Biophys Res Commun       Date:  2006-08-28       Impact factor: 3.575

2.  Structure and enzymatic functions of human CD38.

Authors:  Hon Cheung Lee
Journal:  Mol Med       Date:  2006 Nov-Dec       Impact factor: 6.354

3.  CD38 is associated with premenopausal and postmenopausal bone mineral density and postmenopausal bone loss.

Authors:  Frances J Drummond; John J Mackrill; Kathleen O'sullivan; Mary Daly; Fergus Shanahan; Michael G Molloy
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

Review 4.  Calcium and bone disease.

Authors:  Harry C Blair; Lisa J Robinson; Christopher L-H Huang; Li Sun; Peter A Friedman; Paul H Schlesinger; Mone Zaidi
Journal:  Biofactors       Date:  2011-06-14       Impact factor: 6.113

5.  E proteins regulate osteoclast maturation and survival.

Authors:  Courtney L Long; William L Berry; Ying Zhao; Xiao-Hong Sun; Mary Beth Humphrey
Journal:  J Bone Miner Res       Date:  2012-12       Impact factor: 6.741

6.  Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication.

Authors:  Gang An; Chirag Acharya; Xiaoyan Feng; Kenneth Wen; Mike Zhong; Li Zhang; Nikhil C Munshi; Lugui Qiu; Yu-Tzu Tai; Kenneth C Anderson
Journal:  Blood       Date:  2016-07-14       Impact factor: 22.113

7.  Blocking FSH induces thermogenic adipose tissue and reduces body fat.

Authors:  Peng Liu; Yaoting Ji; Tony Yuen; Elizabeth Rendina-Ruedy; Victoria E DeMambro; Samarth Dhawan; Wahid Abu-Amer; Sudeh Izadmehr; Bin Zhou; Andrew C Shin; Rauf Latif; Priyanthan Thangeswaran; Animesh Gupta; Jianhua Li; Valeria Shnayder; Samuel T Robinson; Yue Eric Yu; Xingjian Zhang; Feiran Yang; Ping Lu; Yu Zhou; Ling-Ling Zhu; Douglas J Oberlin; Terry F Davies; Michaela R Reagan; Aaron Brown; T Rajendra Kumar; Solomon Epstein; Jameel Iqbal; Narayan G Avadhani; Maria I New; Henrik Molina; Jan B van Klinken; Edward X Guo; Christoph Buettner; Shozeb Haider; Zhuan Bian; Li Sun; Clifford J Rosen; Mone Zaidi
Journal:  Nature       Date:  2017-05-24       Impact factor: 49.962

8.  CD38 deficiency in the tumor microenvironment attenuates glioma progression and modulates features of tumor-associated microglia/macrophages.

Authors:  Ayelet Levy; Eran Blacher; Hananya Vaknine; Frances E Lund; Reuven Stein; Lior Mayo
Journal:  Neuro Oncol       Date:  2012-06-14       Impact factor: 12.300

9.  Identification of two-pore channel 2 as a novel regulator of osteoclastogenesis.

Authors:  Takuya Notomi; Yoichi Ezura; Masaki Noda
Journal:  J Biol Chem       Date:  2012-07-25       Impact factor: 5.157

10.  Loading-related regulation of gene expression in bone in the contexts of estrogen deficiency, lack of estrogen receptor alpha and disuse.

Authors:  Gul Zaman; Leanne K Saxon; Andrew Sunters; Helen Hilton; Peter Underhill; Debbie Williams; Joanna S Price; Lance E Lanyon
Journal:  Bone       Date:  2009-10-24       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.